Leading drug makers to cut corrupt ties with doctors

Some of Korea’s leading pharmaceutical firms are turning their eyes to a long-term growth by rooting out the provision of rebates and cut the corrupt ties in a bid to protect patients and ensure the financial stability of health insurance.

They plan to create an environment in which any form of rebate and other unfair practices will no longer be tolerated.

It has long been a “common pract...